Papua New Guinea human T-lymphotropic virus
US5397696A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 12, 1991 |
| Grant date | Mar 14, 1995 |
| Priority date | — |
| Expiry date | Aug 12, 2011 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/14022
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a human T-cell line (PNG-1) persistently infected with a Papua New Guinea (PNG) HTLV-I variant and to the infecting virus (PNG-1 variant). Cells of the present invention express viral antigens, type C particles and have a low level of reverse transcriptase activity. The establishment of this cell line, the first of its kind from an individual from Papua New Guinea, makes possible the screening of Melanesian populations using a local virus strain. The present invention also relates to vaccines for use in humans against infection with and diseases caused by HTLV-I and related viruses. The invention further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-I and related viruses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.